How Geroscience Is Reshaping Dermatology Into a Longevity Medicine Specialty

Longevity medicine is shifting healthcare from reactive disease treatment toward prevention grounded in aging biology. This commentary by Diala Haykal, a cosmetic dermatologist in private practice in France, argues that dermatology sits at a uniquely powerful intersection: skin is simultaneously a visible readout of systemic aging and an accessible tissue for biomarker sampling. The paper synthesizes current evidence from geroscience, AI research, dermatologic aging science, and microbiome biology to propose a translational framework for longevity-oriented clinical dermatology.

The paper centers on biological aging biomarkers and their potential clinical utility. DNA methylation clocks — including the Horvath, GrimAge, and PhenoAge algorithms — are described as among the most validated tools for assessing biological age, with established correlations to morbidity and mortality in research settings. These are complemented by markers of chronic low-grade inflammation ('inflammaging'), senescence-associated secretory phenotype (SASP) factors, NAD⁺/NADH ratios, lactate levels, mitochondrial DNA copy number, and proteomic and transcriptomic profiles reflecting autophagy, DNA repair, and metabolic regulation. Microbiome-derived metabolites — particularly short-chain fatty acids and trimethylamine N-oxide — are flagged as emerging systemic health biomarkers. The author is careful to note that across tissue types, these biomarkers show variable performance depending on environmental exposure, analytic methodology, and the absence of standardized assays validated against skin-specific endpoints.

Artificial intelligence is presented as the enabling layer that makes multidimensional aging data actionable. Machine learning algorithms can identify predictive biomarkers, segment patients by aging phenotype, and simulate intervention outcomes. The commentary highlights 'digital twins' — virtual patient models integrating real-time physiological data with predictive modeling — as a near-future clinical application. In current pilot programs, AI tools are already being used to interpret epigenetic clock outputs, guide lifestyle modification, and forecast responses to senolytics or NAD⁺ boosters. However, the author stresses a critical limitation: AI models trained predominantly on lighter skin phototypes risk producing biased predictions of 'skin age' and inappropriate treatment recommendations. Transparent calibration across the full Fitzpatrick spectrum is described as ethically and clinically essential.

A key contribution of the commentary is a structured table classifying longevity-oriented dermatologic interventions by clinical readiness. Tier one ('clinically established') includes lifestyle optimization, nutrition, sleep, photoprotection, topical formulations, and energy-based devices such as lasers, radiofrequency, and ultrasound — all supported by dermatologic evidence. Tier two ('emerging') covers senotherapeutics (senolytic peptides, rapalogs), NAD⁺ modulation, microbiome-targeted interventions, and AI-assisted diagnostics — in early-phase clinical exploration but not yet standardized. Tier three ('experimental') encompasses exosome-based therapies, stem cell infusions, and gene-editing or reprogramming approaches — currently conceptual or preclinical, lacking validated longevity outcomes in either skin or systemic domains.

The paper closes with substantive ethical and equity analysis. Many longevity diagnostics and interventions fall outside insurance reimbursement frameworks, risking access inequity. Informed consent must evolve to address off-label interventions, biological age data storage, and long-term predictive risk disclosure. Regulatory bodies are beginning to explore frameworks that treat biological age as a clinical endpoint. The author explicitly warns against repeating the unfulfilled promises of prior 'anti-aging' commercial movements, emphasizing that no current intervention has demonstrated prevention or reversal of cancer, Alzheimer's disease, or osteoarthritis. Aging phenotypes also differ by sex, ethnicity, melanin density, dermal thickness, and collagen cross-linking — variations that shape both aging trajectories and the accuracy of AI diagnostic tools, requiring globally representative research datasets.